Cytodyn Inc (CYDY)

[Saltz]

Oh my, what a predicament. Joining forces with the very company that has wanted to squash Leronlimab like a bug.

I will believe the fomo when Gilead releases a PR verifying such an arrangement. From a business perspective partnering up with Gilead to conduct a CV combo trial cements CYDY’s move off the OTC to Nasdaq. Personally I think we are close to making that move organically without R/S or partnership with BP.

As mentioned our current trials would continue and the truth would be known about Leronlimab’s ability to stand as a single agent treatment for CV. So patients would ultimately not be compromised.

If I’m Gilead why do I want to help the very company that poses the biggest threat to my future? In the short term they have created value with Remdesivir by piggy backing Lenronlimab while adding exposure, credibility, and financial strength for what may be their largest competitor. As I said I’ll believe this move by Gilead when it’s formally announced.

This is quite a chess game. If Nader has a strength it’s his negotiating tenacity. Shaping up to be another interesting day for CYDY.